Financial Performance - The company's revenue for Q3 2021 was ¥179,390,590.62, representing a 16.02% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥6,955,330.26, a significant increase of 78.21% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥7,375,415.08, up by 51.34% compared to the same period last year[4] - The basic earnings per share for Q3 2021 was ¥0.04, a 100% increase compared to the same period last year[4] - Total operating revenue for Q3 2021 reached ¥518,143,668.07, an increase of 28.5% compared to ¥403,325,127.76 in Q3 2020[22] - Net profit for Q3 2021 was ¥17,172,369.51, slightly up from ¥17,092,345.30 in Q3 2020, indicating a marginal growth of 0.5%[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥804,910,710.40, a decrease of 11.36% from the end of the previous year[4] - The company's total assets decreased to ¥804,910,710.40 as of September 30, 2021, down from ¥908,087,426.76 at the end of 2020, representing a decline of 11.4%[20] - Current assets totaled ¥329,196,257.00, a decrease of 26.9% from ¥450,252,514.19 at the end of 2020[20] - The total liabilities decreased significantly, with contract liabilities down by 56.39% to CNY 20.66 million, indicating improved revenue recognition[10] - The total liabilities decreased to ¥112,735,784.35 from ¥220,940,937.86, a reduction of 48.9%[21] - Total liabilities amounted to CNY 220,940,937.86, a slight decrease of CNY 168,874.63 compared to the previous period[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥69,249,556.94, an increase of 64.37%[4] - The net cash flow from operating activities increased to CNY 69,249,556.94, compared to CNY 42,129,411.90 in the same period last year[26] - Total cash inflow from operating activities was CNY 965,164,381.49, up from CNY 616,374,344.36 in the previous year[25] - Total cash outflow from operating activities was CNY 895,914,824.55, compared to CNY 574,244,932.46 in the same period last year[25] - The net cash flow from investment activities was negative at CNY -55,205,676.97, worsening from CNY -16,900,961.83 in the previous period[26] - The company experienced a net decrease in cash and cash equivalents of CNY -45,112,907.25 during the period[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,704[13] - The top shareholder, Gao Fan, holds 26.66% of shares, totaling 50,971,482 shares, with 20,485,535 shares pledged[13] - The top ten shareholders hold a combined 56.66% of the shares, indicating significant ownership concentration[13] - The company repurchased and canceled 490,125 restricted stock units due to not meeting performance targets, reducing total shares from 191,769,000 to 191,190,375[17] Research and Development - Research and development expenses surged by 180.10% to CNY 6.93 million, up from CNY 2.47 million in the prior year, reflecting increased investment in R&D projects[10] - The company reported R&D expenses of ¥6,925,510.60 for Q3 2021, significantly higher than ¥2,472,500.96 in Q3 2020, reflecting an increase of 179.5%[22] Acquisitions and Investments - The company acquired 51% of Inner Mongolia Bostai Enterprise Management Service Co., Ltd. for 30.6 million RMB, becoming its controlling shareholder[17] - The company reported a significant increase in goodwill by 375.70% to CNY 36.47 million, primarily due to the acquisition of a 51% stake in Inner Mongolia Bostai[10] - The company has entrusted 21 million RMB in financial management products, with expected returns of 3.20% to 2.85%[16] - The company has a total of 10 million RMB in entrusted financial management with no overdue amounts[16] Governance and Compliance - The company’s board and supervisory board were re-elected on September 13, 2021, completing the governance transition[17] - The third quarter report was not audited, indicating preliminary financial results[32] - The company did not make retrospective adjustments for prior periods under the new standards[31] - The company has adopted new leasing standards starting from 2021, with no significant impact on financial status or cash flow[31] Dividends - A cash dividend of 0.80 RMB per 10 shares was distributed, totaling 15,295,230 RMB[17]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 338,753,077.45, representing a 36.21% increase compared to CNY 248,707,494.89 in the same period last year[22]. - The net profit attributable to shareholders of the listed company decreased by 22.84% to CNY 10,177,542.42 from CNY 13,189,425.35 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 13.67% to CNY 6,664,384.22 compared to CNY 5,863,045.75 in the previous year[22]. - The net cash flow from operating activities surged by 164.64% to CNY 21,337,384.56 from CNY 8,062,900.47 in the same period last year[22]. - Basic earnings per share decreased by 28.57% to CNY 0.05 from CNY 0.07 in the same period last year[22]. - Diluted earnings per share also decreased by 28.57% to CNY 0.05 from CNY 0.07 year-on-year[22]. - The weighted average return on net assets was 1.47%, down from 2.00% in the previous year[22]. - The company's gross profit margin decreased due to a higher increase in operating costs, which rose by 41.73% to ¥224,213,354.01 from ¥158,200,544.94 in the previous year[44]. - The company's net profit attributable to shareholders decreased by 22.84% year-on-year due to a 41.73% increase in operating costs and a 38.73% increase in selling expenses, both outpacing revenue growth[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 808,019,376.67, down 11.02% from CNY 908,087,426.76 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company decreased by 0.60% to CNY 683,012,629.91 from CNY 687,146,488.90 at the end of the previous year[22]. - The company's total liabilities decreased to CNY 125,006,746.76 from CNY 220,940,937.86, a reduction of about 43%[149][150]. - The company's current assets decreased to CNY 359,834,569.86 from CNY 450,252,514.19, reflecting a reduction of about 20%[147][148]. - Cash and cash equivalents dropped to CNY 142,867,586.31 from CNY 205,321,751.59, indicating a decrease of approximately 30%[147]. Revenue Sources and Growth - The company achieved a sales revenue of 338.75 million yuan, representing a year-on-year growth of 36.21%[35]. - The sales growth was primarily driven by third-party cooperative products such as Gua Lou Pi Injection, Sodium Nemephene Injection, and self-produced products like Miglitol Tablets and Domperidone Tablets[44]. - The cardiovascular segment generated ¥153,682,372.45, accounting for 45.37% of total revenue, with a year-on-year growth of 49.53%[48]. - Revenue from the cardiovascular sector increased by 49.53%, while revenue from the Gua Lou Pi injection (product sales) and (market promotion) rose by 94.31% and 45.80% respectively compared to the previous year[52]. - Revenue from the "other" sector grew by 54.28%, while costs in this sector increased by 65.49%, primarily due to the entry of Domperidone tablets into national centralized procurement[52]. Research and Development - Research and development expenses increased by 32.24% to ¥5,855,631.00, up from ¥4,428,099.20 in the previous year[46]. - The company is actively involved in the development of new products, including the raw material and injection project for L-arginine, aimed at treating patent ductus arteriosus (PDA)[35]. - The company has established a comprehensive R&D and production capability, with three R&D centers and two production centers, ensuring a strong competitive edge in product development[41]. Environmental Responsibility - The company is committed to environmental protection and has implemented measures to achieve energy conservation and emission reduction[37]. - The company has a daily wastewater treatment capacity of 450 tons, with an inflow COD concentration of approximately 2500 mg/L and an outflow COD concentration of 100 mg/L, significantly below the standard of 300 mg/L[84]. - The company has obtained a national pollutant discharge permit, with the permit number 91510000620854656KP001, which can be verified on the national pollutant discharge permit management information platform[86]. - The company has implemented a self-monitoring plan for pollutants, with wastewater monitored quarterly and air emissions monitored biannually[86]. Shareholder and Investor Relations - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes a long-term stable profit distribution policy, prioritizing cash dividends to return value to shareholders[89]. - The company has maintained a focus on social responsibility, ensuring the protection of shareholder rights and enhancing investor relations through effective communication[88]. - The company completed the repurchase and cancellation of 490,125 restricted stock units due to not meeting performance targets for the previous year[81]. Miscellaneous - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations[83]. - The financial report for the first half of 2021 was not audited[145]. - The company has not engaged in any significant related party transactions during the reporting period[104]. - The company has not encountered any major litigation or arbitration matters during the reporting period[102].

Financial Performance - The company's revenue for Q1 2021 was ¥158,204,489.91, representing a 64.65% increase compared to ¥96,087,140.09 in the same period last year[9] - Net profit attributable to shareholders decreased by 11.89% to ¥5,259,104.57 from ¥5,968,919.24 year-on-year[9] - Revenue for Q1 2021 reached ¥158.20 million, an increase of 64.65% compared to ¥96.09 million in Q1 2020[17] - Net profit for Q1 2021 was CNY 5.26 million, a decrease of 11.9% from CNY 5.97 million in Q1 2020[40] - The net profit for the current period was ¥1,108,475.93, compared to a net loss of ¥2,553,737.01 in the previous period, marking a turnaround[43] - The total comprehensive income for the current period was ¥1,108,475.93, compared to a loss of ¥2,553,737.01 in the previous period[44] Cash Flow - The net cash flow from operating activities improved by 99.44%, reaching -¥9,808,758.10 compared to -¥13,919,475.18 in the previous year[9] - The company reported a cash inflow from operating activities of ¥244,581,040.38, an increase from ¥175,601,844.94 in the previous period[46] - The net cash flow from operating activities was negative at -¥9,808,758.10, an improvement from -¥13,919,475.18 in the previous period[46] - In Q1 2021, the net cash flow from operating activities was -CNY 40,533,386.53, compared to -CNY 33,969,541.34 in Q1 2020, indicating a decline in cash flow[49] - The company reported a total cash outflow from operating activities of CNY 278,392,381.63 in Q1 2021, an increase of 59.5% compared to CNY 174,713,027.43 in Q1 2020[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥876,006,443.91, a decrease of 3.53% from ¥908,087,426.76 at the end of the previous year[9] - The company's total assets as of March 31, 2021, amounted to CNY 701.56 million, down from CNY 708.08 million at the end of 2020[36] - The company's current assets decreased from ¥450,252,514.19 at the end of 2020 to ¥422,382,680.95, representing a decline of about 6.2%[31][32] - Total liabilities decreased from ¥220,940,937.86 to ¥183,047,976.21, a reduction of about 17.2%[33][34] - The total liabilities decreased to CNY 117.91 million from CNY 126.09 million at the end of 2020, a reduction of 6.5%[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,136[13] - The largest shareholder, Gao Fan, holds 26.46% of the shares, amounting to 50,744,682 shares, with a portion pledged[13] - The company's equity attributable to shareholders increased from ¥687,146,488.90 to ¥692,958,467.70, reflecting a growth of approximately 0.6%[34] Research and Development - R&D expenses surged by 741.06% to ¥5.05 million, up from ¥0.60 million in Q1 2020, indicating a significant increase in investment in innovation[17] - Research and development expenses decreased to ¥25,259.60 from ¥151,691.67, indicating a reduction in investment in this area[42] Compliance and Governance - The company reported no non-compliance with external guarantees during the reporting period[26] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[27] - The company did not engage in any research, communication, or interview activities during the reporting period[28] Financial Adjustments - The company adopted new leasing standards starting from January 1, 2021, which resulted in adjustments to the financial statements without significant impact on financial status or cash flows[53] - The company adopted the new leasing standards starting from Q1 2021, with no significant impact on financial status, operating results, or cash flow[56]

Financial Performance - The company's operating revenue for 2020 was CNY 602,619,263.55, representing an increase of 8.92% compared to CNY 553,255,391.08 in 2019[18]. - The net profit attributable to shareholders for 2020 was CNY 41,091,164.30, which is a 10.08% increase from CNY 37,328,950.93 in 2019[18]. - The net cash flow from operating activities increased by 71.84% to CNY 101,735,689.50 in 2020, up from CNY 59,202,426.13 in 2019[18]. - The basic earnings per share for 2020 was CNY 0.22, reflecting a 10.00% increase from CNY 0.20 in 2019[18]. - Total assets at the end of 2020 were CNY 908,087,426.76, an increase of 8.70% from CNY 835,405,794.28 at the end of 2019[18]. - The net assets attributable to shareholders at the end of 2020 were CNY 687,146,488.90, which is a 5.36% increase from CNY 652,168,993.82 at the end of 2019[18]. - The company reported a decrease of 5.14% in net profit after deducting non-recurring gains and losses, totaling CNY 31,854,012.56 in 2020 compared to CNY 33,580,742.15 in 2019[18]. - The weighted average return on net assets for 2020 was 6.14%, up from 5.88% in 2019[18]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 0.8 per 10 shares, based on a total of 191,190,375 shares[5]. - In 2020, the company distributed cash dividends of 15,295,230.00 CNY, which is 37.22% of the net profit attributable to ordinary shareholders[110]. - The profit distribution plan for 2020 proposes a cash dividend of 0.80 CNY per 10 shares, totaling 15,295,230.00 CNY, subject to approval at the annual general meeting[113]. Revenue Segmentation - The cardiovascular segment generated ¥253,443,333.34, accounting for 42.06% of total revenue, with a year-over-year decrease of 5.31%[50]. - The diabetes segment saw significant growth, with revenue of ¥149,415,468.45, a 59.54% increase from ¥93,655,968.14 in 2019[50]. - The gynecology segment reported revenue of ¥124,211,681.72, reflecting a 9.86% increase compared to the previous year[50]. - The revenue from the company's main product, Guo Lao Pi injection, accounted for 42% of total revenue during the reporting period, indicating a decreasing reliance on a single product[102]. Cash Flow and Investments - Operating cash inflow increased by 12.62% year-on-year to ¥766,738,008.28, while operating cash outflow rose by 6.98% to ¥665,002,318.78, resulting in a net cash flow from operating activities of ¥101,735,689.50, up 71.84%[62]. - The company reported a significant decrease in investment cash inflow by 68.77% to ¥120,581,567.48, and a 78.06% decrease in investment cash outflow to ¥128,429,041.66[62]. - The total investment amount for the reporting period was ¥38,429,041.66, a decrease of 77.45% compared to the previous year's investment of ¥170,451,132.29[75]. Research and Development - The company has established a complete R&D and production capability with three R&D centers and two production centers, ensuring a leading advantage in R&D[37]. - The number of R&D personnel increased by 2.00% to 51, while R&D investment amounted to ¥9,521,061.03, representing 1.58% of operating revenue[60]. - R&D expenses increased by 37.05% year-on-year to ¥6,847,908.92, reflecting the company's commitment to advancing its R&D initiatives[59]. Market Strategy and Expansion - The company plans to enhance its product development and market expansion strategies in the coming years, leveraging its existing partnerships and product lines[32]. - The company aims to actively participate in national drug centralized procurement to boost short-term revenue growth[98]. - The company plans to invest in building a biopharmaceutical R&D platform and seek partnerships with domestic and international biopharmaceutical firms to introduce mature clinical projects[100]. - The company is focusing on building an OTC sales team to expand its market presence and improve patient service[99]. Corporate Governance and Compliance - The company is committed to enhancing its governance structure and management capabilities to ensure efficient operations amid its expanding asset scale[103]. - The company reported a commitment to compensate investors for losses caused by false statements or omissions in the issuance documents[119]. - The company has established a framework for accountability among its executives in case of non-compliance with public commitments[121]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, including donations of disinfectants and masks to support COVID-19 prevention efforts[45]. - The company has created 44 job opportunities, including 7 for local Tibetan residents, as part of its commitment to local employment[47]. - The total investment in poverty alleviation efforts amounted to 34.5 million yuan, with additional material donations valued at 20.57 million yuan[172]. Shareholder Information - The total number of shares decreased from 193,210,000 to 191,769,000 due to the repurchase and cancellation of 1,441,000 restricted shares[181]. - The largest shareholder, Gao Fan, holds 26.46% of the shares, totaling 50,744,682 shares, with 24,414,645 shares pledged[191]. - The company’s total share capital after the repurchase is now 191,769,000 shares[187]. Risk Management - The company acknowledges risks related to regulatory changes in the pharmaceutical industry, which could impact its future operational performance[102]. - The company emphasizes the importance of risk awareness regarding its reliance on specific products and industry policies[5].

Financial Performance - Operating revenue for the reporting period was CNY 154,617,632.87, an increase of 31.21% year-on-year[8] - Net profit attributable to shareholders was CNY 3,902,919.95, reflecting a growth of 6.14% compared to the same period last year[8] - Total operating revenue for Q3 2020 reached ¥154,617,632.87, compared to ¥117,837,821.12 in the previous period, indicating a growth of approximately 31.2%[46] - Net profit for Q3 2020 was ¥3,902,919.95, compared to ¥3,676,971.21 in the same period last year, showing a growth of approximately 6.1%[48] - The net profit for the current period is 17,092,345.30, an increase from 15,611,341.88 in the previous period, indicating a growth of approximately 9.5%[56] - The net profit for the current period was a loss of ¥10,264,586.90, compared to a profit of ¥1,722,769.45 in the previous period, indicating a significant decline[60] Cash Flow - Net cash flow from operating activities increased significantly by 232.24% to CNY 34,066,511.43[8] - The net cash flow from operating activities was ¥42,129,411.90, a recovery from a negative cash flow of ¥4,667,121.46 in the previous period[62] - The net cash flow from operating activities for the period was ¥84,467,087.03, a significant improvement compared to the previous period's net cash flow of -¥132,224,979.79[64] - Total cash inflow from operating activities reached ¥624,704,539.11, up from ¥423,194,485.13 in the previous period, indicating a growth of approximately 47.5%[64] Assets and Liabilities - Total assets at the end of the reporting period were CNY 833,478,346.72, a decrease of 0.23% compared to the end of the previous year[8] - The company's current assets decreased to ¥376,725,288.34 from ¥400,567,707.61, reflecting a decline of approximately 5.9%[37] - The total liabilities decreased to ¥168,929,188.93 from ¥183,236,800.46, representing a decline of about 7.8%[39] - Total liabilities decreased to ¥79,004,402.72 in Q3 2020 from ¥131,400,049.49 in the previous period, a reduction of approximately 40%[44] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,674[12] - The largest shareholder, Gao Fan, holds 26.46% of the shares, with 50,744,682 shares pledged[12] Expenses and Costs - Total operating costs for Q3 2020 were ¥148,717,393.09, up from ¥114,170,579.44 in the previous period, reflecting an increase of about 30.2%[47] - The company's financial expenses decreased by ¥8.99 million year-on-year, a reduction of 56.74%, primarily due to a decrease in total loan amounts and corresponding interest payments[11] - Research and development expenses for Q3 2020 were ¥1,194,360.82, compared to ¥932,100.92 in the previous period, reflecting an increase of approximately 28.2%[47] Government Support - The company received government subsidies amounting to CNY 3,951,051.58, primarily from local support policies[9] - The company’s other income rose by ¥57.08 million, an increase of 32.43%, due to government subsidies received for meeting economic contribution standards[12] Investment Activities - The company reported a net investment cash flow of -¥169.01 million, a decrease of 90.35% compared to the previous year, primarily due to reduced cash outflows for short-term financial products[17] - The company reported a total investment cash outflow of ¥87,221,470.60, compared to ¥501,186,552.32 in the previous period, indicating a reduction in investment activities[63] Earnings Per Share - The basic earnings per share remained at CNY 0.02, unchanged from the previous period[8] - The company reported a basic and diluted earnings per share of -0.03, compared to 0.01 in the previous period[53] - Basic and diluted earnings per share for the current period are both 0.09, compared to 0.08 in the previous period, reflecting a slight increase[57] Other Financial Metrics - The weighted average return on net assets was 0.59%, showing no change from the previous period[8] - The company reported no significant changes in its non-recurring gains and losses during the reporting period[10] - The company has no reported non-operating fund occupation by controlling shareholders or related parties during the reporting period[31] - There were no violations regarding external guarantees during the reporting period[30]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 248,707,494.89, representing an increase of 8.44% compared to CNY 229,343,336.92 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 13,189,425.35, up by 10.52% from CNY 11,934,370.67 year-on-year[18]. - The net profit after deducting non-recurring gains and losses decreased by 40.29%, amounting to CNY 5,863,045.75 compared to CNY 9,819,281.47 in the previous year[18]. - The net cash flow from operating activities was CNY 8,062,900.47, a decline of 61.78% from CNY 21,094,068.90 in the same period last year[18]. - The total assets at the end of the reporting period were CNY 897,541,565.04, reflecting a growth of 7.44% from CNY 835,405,794.28 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were CNY 659,724,842.79, which is an increase of 1.16% from CNY 652,168,993.82 at the end of the previous year[18]. - The basic earnings per share increased by 16.67% to CNY 0.07 from CNY 0.06 in the same period last year[18]. - The company's total non-operating income for the reporting period was CNY 7,326,379.60, with a tax impact of CNY 1,039,103.14[23]. - The company reported a net cash flow from financing activities of CNY 32,055,133.34, an increase of 37.58% compared to CNY 23,300,050.72 in the previous year[48]. - The cash and cash equivalents increased by CNY 40,631,048.64, compared to a decrease of CNY 42,848,390.93 in the same period last year[48]. Business Operations - The company has successfully developed a range of proprietary and third-party cooperative pharmaceutical products, including Miglitol tablets and Montmorillonite powder, which fill market gaps[26][28]. - The company holds exclusive promotion rights for several cooperative products, including Guo Lou Pi injection and Sodium Nifedipine injection, with established partnerships ensuring stable supply and quality[29]. - The company is expanding its raw material sales business, with Miglitol raw materials already registered in India and Taiwan[33]. - The company is actively optimizing its marketing organization and enhancing its sales network to support product sales growth[38]. - The company has established a comprehensive R&D and production capability with three R&D centers and two production centers across Beijing, Chengdu, and Lhasa[34]. - The company is participating in the development of industry-leading standards and has advanced production technologies, including automation and modernization[34]. - The company’s products, including Dronabinol tablets (维动啉®), won bids in the third batch of national drug centralized procurement[38]. - The company is focusing on the consistency evaluation of generic drugs, with several products like Loratadine tablets and Metformin hydrochloride tablets undergoing evaluation[34]. Market and Product Development - The company’s flagship product, Miglitol tablets (奥恬苹®), maintained the leading market share in the Miglitol formulation market in China[31]. - The company has successfully developed and marketed several key products, including the first generic version of Carboprost injection (鑫诺舒®) and the first approved Montmorillonite powder (贝易平®) in China[32][33]. - Revenue from the diabetes segment increased by 71.48% to CNY 64,697,232.85, driven by enhanced academic promotion and sales terminal development efforts[53]. - The cardiovascular segment's revenue decreased by 10.58% to CNY 102,777,317.33, accounting for 41.32% of total revenue[50]. - The revenue from the product "Miglitol tablets" surged by 71.48%, contributing significantly to the overall revenue growth[53]. Investment and Financial Strategy - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company maintained a debt ratio of around 26%, significantly lower than the pharmaceutical industry average, ensuring a favorable competitive position[41]. - R&D investment grew by 26.44% year-on-year, totaling approximately ¥4.43 million, reflecting the company's commitment to enhancing product quality and consistency[47]. - The company has committed to maintaining a stable stock price and will initiate measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days[117]. - The company plans to implement a stock repurchase program, with a single repurchase amount not exceeding 20% of the previous year's audited net profit attributable to shareholders[118]. Corporate Governance and Compliance - The company plans to enhance its corporate governance structure and management capabilities to support its expanding asset scale and ensure operational efficiency[94]. - The company emphasizes strict adherence to new GMP and GSP standards to mitigate drug quality risks and ensure product safety[94]. - The company has established strict compliance measures for share reduction to maintain market integrity and investor confidence[107]. - The company will ensure compliance with legal and regulatory requirements when implementing stock price stabilization measures[117]. - The company has committed to compensating investors for any losses caused by unfulfilled public commitments[132]. Social Responsibility - The company has actively participated in social responsibility initiatives, including donations of disinfectants and protective equipment to support pandemic prevention efforts[42]. - The company has invested a total of 2.6 million yuan in poverty alleviation efforts, including 204,600 yuan in material donations[175]. - The company plans to continue its participation in pandemic response activities and organize medical expert visits to provide free medical consultations in Tibetan areas[176]. Shareholder Information - The company has a profit distribution policy that emphasizes stable and continuous returns to investors, contingent on good operational conditions and sufficient cash flow[112]. - The largest shareholder, Gao Fan, holds 26.26% of the shares, totaling 50,744,682 shares, with 24,414,645 shares pledged[184]. - The company has a total of 59,500,638 restricted shares, accounting for 30.80% of the total shares[181]. - The company has not reported any new strategies or market expansions in the current period[186].

Financial Performance - The company's operating revenue for 2019 was CNY 553,255,391.08, representing a 13.19% increase compared to CNY 488,774,206.55 in 2018[19] - The net profit attributable to shareholders for 2019 was CNY 37,328,950.93, a significant increase of 47.81% from CNY 25,255,041.15 in 2018[19] - The net profit after deducting non-recurring gains and losses was CNY 33,580,742.15, which is a 95.07% increase compared to CNY 17,214,717.68 in 2018[19] - The net cash flow from operating activities reached CNY 59,202,426.13, marking a substantial increase of 344.67% from CNY 13,313,864.60 in 2018[19] - The basic earnings per share for 2019 was CNY 0.20, up 53.85% from CNY 0.13 in 2018[19] - Total assets at the end of 2019 were CNY 835,405,794.28, reflecting a 10.22% increase from CNY 757,933,697.51 at the end of 2018[19] - The net assets attributable to shareholders increased by 5.46% to CNY 652,168,993.82 at the end of 2019, compared to CNY 618,400,811.60 at the end of 2018[19] - The weighted average return on equity for 2019 was 5.88%, an increase from 4.14% in 2018[19] Revenue Breakdown - Cardiovascular products generated ¥267.66 million, accounting for 48.38% of total revenue, with a slight increase of 1.23% year-on-year[52] - Diabetes products saw a revenue increase of 15.66%, totaling ¥93.66 million, maintaining a stable revenue share of 16.93%[49] - Gynecological products experienced significant growth of 41.08%, reaching ¥113.06 million, up from ¥80.14 million in 2018[49] - The sales of the product "Gua Lou Pi Injection (Market Promotion)" increased by 7.87% to ¥258.37 million, representing 46.70% of total revenue[52] - The Northeast region contributed ¥159.49 million, a 13.34% increase from the previous year, maintaining a 28.83% share of total revenue[50] Investments and Projects - The company invested a total of 140.63 million yuan in fundraising projects during the reporting period[43] - The marketing network integration project reached a completion rate of 76.23% with an investment of 37.96 million yuan[43] - The construction in progress increased by 156.55 million yuan, mainly due to the ongoing investments in the "Montmorillonite API and formulation production line and supporting warehouse construction project" and the "New API workshop and production line supporting project" during the period[32] - The company has ongoing investments in the new raw material drug workshop and production line, with an investment of 23,608,684.91, currently at 88.09% completion[78] - The montmorillonite raw material drug and formulation production line project has completed engineering acceptance as of November 20, 2019, and is currently in trial production[88] Research and Development - The company has established a complete R&D and production capability, with three R&D centers and two production centers, ensuring a leading advantage from project initiation to results[36] - The total R&D investment was ¥9,320,170.13, which is 1.68% of operating income, down from 3.86% in 2018[63] - The company is actively participating in the consistency evaluation of several key products, which, if successful, could become new profit growth points[36] - The company is investing 100 million yuan in R&D for new technologies to enhance product efficacy and safety[126] Market Strategy and Expansion - The company aims to expand its market presence through strategic partnerships and innovative product offerings[31] - The company plans to focus on product advantages and expand its market presence through refined marketing and academic promotion strategies in 2020[100] - Market expansion efforts include entering three new provinces in China, targeting a 10% increase in market penetration[126] - The company is considering strategic acquisitions to bolster its product portfolio and enhance competitive positioning[126] Risk Management - The company faces various risks including reliance on specific business collaborations and industry policy risks, which are detailed in the report[6] - The company is facing risks from strict regulatory changes in the pharmaceutical industry, which may compress profit margins and intensify competition[104] - The ongoing COVID-19 pandemic poses risks to the company's operations, potentially affecting drug research, production, and sales[105] - The company recognizes the impact of the COVID-19 pandemic on its operations and will adapt its strategies to mitigate risks and maintain production and supply[99] Corporate Governance and Compliance - The company has not encountered any significant changes in the feasibility of the investment projects as of the reporting period[85] - The company has not faced any major litigation or arbitration matters during the reporting period[167] - The company has not undergone any bankruptcy reorganization during the reporting period[166] - The company has maintained a continuous relationship with its auditing firm for 7 years, with the current audit fee set at 600,000 CNY[165] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of CNY 0.4 per 10 shares, based on a total of 191,769,000 shares[6] - The company reported a cash dividend of 0.40 yuan per share for 2019, totaling 7,670,760.00 yuan, which represents 20.55% of the net profit attributable to ordinary shareholders[113] - The company has maintained its cash dividend policy without adjustments during the reporting period[109] - The proposed cash dividend distribution for 2019 is 0.40 CNY per share, totaling 7,670,760.00 CNY, which represents 21.60% of the distributable profit after surplus reserve allocation[115] Environmental and Social Responsibility - The company was recognized as an environmentally friendly enterprise by the Chengdu Ecological Environment Bureau, highlighting its commitment to environmental protection and sustainable development[200] - The company is committed to fulfilling its social responsibility by participating in poverty alleviation efforts in Tibet, including employment support and donations[102]

Financial Performance - The company's revenue for Q1 2020 was ¥96,087,140.09, representing a decrease of 9.30% compared to ¥105,939,655.33 in the same period last year[9] - Net profit attributable to shareholders was ¥5,968,919.24, down 9.11% from ¥6,567,136.39 year-on-year[9] - The net profit after deducting non-recurring gains and losses was -¥1,393,743.13, a decline of 124.76% compared to ¥5,628,563.52 in the previous year[9] - Operating profit for Q1 2020 was -6,149,867.27 CNY, down from 4,073,890.01 CNY in Q1 2019, indicating a negative shift in operational performance[48] - The company reported a total comprehensive income of -2,553,737.01 CNY for Q1 2020, compared to 3,535,253.88 CNY in the same period last year, highlighting overall financial challenges[48] Cash Flow - The net cash flow from operating activities was -¥13,919,475.18, worsening by 91.57% from -¥7,265,933.10 in the same period last year[9] - Operating cash flow decreased by 91.57% to -¥13.92 million, impacted by the delay in receiving government funds[17] - The company experienced a net cash outflow from operating activities of -13,919,475.18 CNY, worsening from -7,265,933.10 CNY in the previous year[52] - Cash inflow from financing activities totaled 70,000,000.00 CNY, while cash outflow was 70,609,000.00 CNY, resulting in a net cash flow of -70,609,000.00 CNY[56] - The net increase in cash and cash equivalents was -74,291,942.57 CNY, with a closing balance of 23,235,731.50 CNY[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥769,755,220.24, a decrease of 7.86% from ¥835,405,794.28 at the end of the previous year[9] - The company's total assets decreased to CNY 656,935,371.77 from CNY 714,785,218.59, representing a reduction of 8.1%[41] - The total liabilities decreased from CNY 183,236,800.46 to CNY 110,584,788.55, a reduction of approximately 39.5%[35] - The company's current assets decreased to CNY 328,668,432.07 from CNY 400,567,707.61, representing a reduction of about 18%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,569[13] - The largest shareholder, Gao Fan, holds 26.26% of the shares, amounting to 50,744,682 shares[13] Government Support - The company received government subsidies totaling ¥4,584,750.01, primarily related to business support and clinical approvals[10] - The company received a total of ¥150 million in subsidies for clinical approvals and market compensation during the reporting period[18] - Other income surged by 4815.94% to ¥3.08 million, mainly from government subsidies[17] Expenses - Total operating costs for Q1 2020 were CNY 95,674,672.74, down from CNY 101,154,273.21, reflecting a reduction of 5.0%[42] - Research and development expenses increased to CNY 600,076.62 from CNY 514,162.37, showing a growth of 16.7%[42] - Sales expenses for Q1 2020 were 16,239,071.24 CNY, down from 18,409,703.51 CNY in Q1 2019, suggesting cost control measures[48] Other Information - The company reported no derivative investments during the reporting period[26] - There were no instances of non-compliance with external guarantees during the reporting period[27] - The company did not engage in any non-operating fund occupation by controlling shareholders or related parties[28] - The company did not conduct any research, communication, or interview activities during the reporting period[29] - The first quarter report was not audited[58]

Financial Performance - Net profit attributable to shareholders increased by 180.60% to ¥3,676,971.21 for the reporting period[9] - Basic earnings per share increased by 200.00% to ¥0.02[9] - The company reported a net profit margin of approximately 3% for the current period, reflecting ongoing cost management challenges[43] - The net profit for Q3 2019 was CNY 3,676,971.21, a significant recovery from a net loss of CNY 4,562,114.93 in the previous year[49] - The total profit for Q3 2019 was CNY 4,578,634.52, compared to a total loss of CNY 4,100,850.02 in Q3 2018[49] - The company's operating profit for Q3 2019 was CNY 4,892,056.49, a turnaround from an operating loss of CNY 3,951,234.12 in Q3 2018[49] - The net profit for Q3 2019 reached CNY 15,611,341.88, up 42.67% from CNY 10,950,985.37 in Q3 2018[54] - The total profit for Q3 2019 was CNY 19,241,766.79, representing a 45.56% increase from CNY 13,206,628.61 in Q3 2018[54] Revenue and Income - Operating income for the reporting period was ¥117,837,821.12, a decrease of 1.50% year-on-year[9] - Total operating revenue for Q3 2019 was CNY 117,837,821.12, a decrease from CNY 119,634,634.24 in the previous period[43] - The company's operating revenue for Q3 2019 was CNY 99,127,683.25, an increase of 6.0% compared to CNY 92,735,436.49 in the same period last year[49] - The company's operating revenue for Q3 2019 was CNY 289,581,768.64, an increase of 14.98% compared to CNY 251,802,342.24 in the same period last year[58] Cash Flow - The net cash flow from operating activities was -¥25,761,190.36, a significant decline of 5,659.54% compared to the previous period[9] - Net cash flow from operating activities improved by 76.60% to -¥4,667,121.46, reflecting better management of sales collections and government subsidies received[18] - The net cash flow from financing activities increased by 46.40% to ¥40,517,650.01, primarily due to new short-term borrowings and employee stock incentive contributions[18] - The net cash flow from operating activities was -4,667,121.46 CNY, an improvement from -19,944,627.60 CNY in the previous period, indicating a reduction in cash outflow[63] - The total cash inflow from operating activities was 466,809,290.13 CNY, compared to 482,643,586.86 CNY in the previous period, indicating a slight decline[63] Assets and Liabilities - Total assets at the end of the reporting period reached ¥803,738,229.99, an increase of 6.04% compared to the end of the previous year[9] - The company's total equity increased to CNY 624,663,705.17 from CNY 618,400,811.60, showing a slight improvement in shareholder value[37] - Total liabilities increased to CNY 179,074,524.82 from CNY 139,532,885.91, reflecting a rise in financial obligations[37] - Cash and cash equivalents decreased by 58.35% to ¥99,430,260.68, primarily due to investments in financial products and payments for various projects totaling approximately ¥79 million[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 21,661[13] - The largest shareholder, Gao Fan, holds 26.75% of the shares, with 33,814,645 shares pledged[13] - The company did not engage in any repurchase transactions during the reporting period[14] Expenses - Operating costs rose by 78.84% to ¥220,635,376.93, driven by increased revenue and changes in accounting practices following the implementation of the "two-invoice system" policy[20] - Sales expenses decreased by 48.99% to ¥80,925,961.08, attributed to the same accounting changes and the new business model for cooperative products[20] - Financial expenses increased by 228.74% to ¥1,583,491.07, mainly due to the rise in short-term borrowings[20] - The company reported a 60.95% increase in income tax expenses to ¥3,630,424.91, linked to improved sales performance and profitability of its subsidiary, Vio Pharmaceutical[20] Research and Development - Research and development expenses were CNY 932,100.92, compared to a negative expense of -CNY 968,786.74 in the previous period, indicating increased investment in innovation[43] - The research and development expenses for Q3 2019 were CNY 33,646.38, up from CNY 22,400.44 in the previous year[49] - The company reported a decrease in research and development expenses to CNY 60,999.99 from CNY 121,691.88 year-over-year[58] Government Subsidies - The company received government subsidies totaling ¥1,760,503.64, primarily related to clinical approval and technology investment[10] Financial Management - The total amount of entrusted financial management reached 38,500,000 CNY, with an outstanding balance of 6,000,000 CNY[26] - There were no overdue amounts in entrusted financial management, indicating effective risk management[26] - The company has engaged in various financial products, including bank wealth management products, with a total investment of 38,500,000 CNY[26]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 229,343,336.92, representing a 6.00% increase compared to CNY 216,360,006.28 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 23.07% to CNY 11,934,370.67 from CNY 15,513,100.30 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was CNY 9,819,281.47, down 29.56% from CNY 13,939,566.01 in the previous year[17]. - The basic earnings per share decreased by 25.00% to CNY 0.06 from CNY 0.08 in the same period last year[17]. - The diluted earnings per share also decreased by 25.00% to CNY 0.06 from CNY 0.08 year-on-year[17]. - The weighted average return on net assets was 1.92%, down from 2.54% in the previous year[17]. - The company reported a total revenue of 500 million in the first half of 2019, representing a 15% increase year-over-year[97]. - The company expects a revenue growth of 10% for the second half of 2019, projecting total revenue to reach approximately 1 billion for the full year[97]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to CNY 21,094,068.90, a 203.36% increase from a negative CNY 20,407,996.49 in the same period last year[17]. - The net cash flow from investing activities decreased by 52.81% to -¥87,242,510.55, primarily due to reduced outflows for principal-protected financial products[45]. - The net cash flow from financing activities decreased by 17.15% to ¥23,300,050.72, as repayments of short-term loans and interest payments increased[45]. - The company reported a significant increase in prepayments, which rose to ¥51,741,750.44 from ¥7,338,013.82, a growth of approximately 608.5%[181]. - The cash received from investment recoveries was CNY 290,000,000.00, a significant increase from CNY 10,000,000.00 in the same period last year[200]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 780,323,291.78, up 2.95% from CNY 757,933,697.51 at the end of the previous year[17]. - The company's total liabilities increased to ¥155,612,161.51 from ¥139,532,885.91, marking an increase of about 11.5%[184]. - The total equity attributable to shareholders rose to ¥624,711,130.27 from ¥618,400,811.60, showing a slight increase of approximately 1.9%[184]. - The company's current assets decreased to ¥426,832,931.91 from ¥464,216,840.03, reflecting a decline of about 8.0%[181]. - Cash and cash equivalents decreased to ¥195,858,666.26 from ¥238,707,057.19, a reduction of approximately 17.9%[181]. Research and Development - Research and development investment decreased by 57.74% to ¥3,502,076.82, attributed to project progress[44]. - The company is investing 30 million in R&D for new technologies aimed at enhancing product efficiency[97]. - The company completed the registration and acceptance of the consistency evaluation for Miglitol tablets, with the evaluation for Domperidone tablets progressing in an orderly manner[39]. Market Position and Product Development - The company operates in five main business models: self-produced pharmaceuticals, third-party cooperative pharmaceuticals, raw materials, pharmaceutical raw materials sales, and pharmaceutical promotion services[25]. - The company has established a strong market position with its proprietary Miglitol raw materials, which dominate the domestic market share[33]. - The company plans to increase its raw material sales business, leveraging its advantages in production processes and quality control[33]. - The company’s product portfolio includes unique offerings such as the first generic Miglitol tablets and the only traditional Chinese medicine injection for coronary heart disease, enhancing its competitive edge[33]. - The sales of key products such as Miglitol tablets, Carboprost injection, Montmorillonite powder, and Hongjin Xiaojie tablets all experienced growth during the reporting period[38]. Shareholder and Dividend Policies - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has committed to a profit distribution policy prioritizing cash dividends, with a minimum cash dividend ratio of 80% for mature stages without significant capital expenditures[109]. - The company plans to distribute at least 20% of the annual distributable profit in cash during the first three years post-listing, subject to meeting cash dividend conditions[109]. - The company will not reduce its holdings of shares within 12 months post-listing, with a commitment to adhere to legal regulations regarding share reduction[108]. Corporate Governance and Compliance - The company will establish a sound corporate governance structure to improve management levels and ensure stable operations amid rapid expansion[86]. - The company emphasizes strict compliance with the new GMP and GSP requirements to ensure product quality and safety[86]. - The company has committed to compensating investors for losses due to false statements or omissions in its prospectus, ensuring investor protection[116]. - The company will ensure that any profits gained from non-compliance will be returned to the company[124]. Social Responsibility and Environmental Initiatives - The company has invested a total of 3.30 million yuan in poverty alleviation efforts during the reporting period, including direct financial support and material donations[153]. - The company emphasizes environmental protection and has established facilities to treat waste emissions to meet national and local standards[151]. - The company plans to continue its poverty alleviation efforts by engaging national medical experts for free medical consultations in Tibetan areas and supporting local communities[156].